Benjamin Chilcutt
Jackson, MSNPI 1225563463
Payments from drug & device makers
What this record shows
This record is dominated by grants: $27,137 of the $42,323 with a category attached, or 64.1%. Abbott accounts for 68.4% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2024 at $21,369 and has fallen 79.8% since, to $4,323 in 2025.
Across 153 payments — averaging $276.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$29K
- Boston Scientific$8K
- Medical Device Business Services, Inc.$2K
- Philips North America LLC$1K
- Medtronic$825
- Biosense Webster, Inc.$698
- plus $977 from 7 others
What the payments were for
- Grants$27,13764%
- Travel & lodging$9,00421%
- Food & beverage$5,07612%
- Education$1,1073%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 25 | $28,949 |
| Boston Scientific | 37 | $7,554 |
| Medical Device Business Services, Inc. | 17 | $2,237 |
| Philips North America LLC | 11 | $1,085 |
| Medtronic | 11 | $825 |
| Biosense Webster, Inc. | 30 | $698 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $536 |
| Biotronik Inc. | 2 | $134 |
| Novo Nordisk | 1 | $114 |
| Abiomed | 4 | $99 |
| Pfizer | 3 | $43 |
| Merck | 2 | $35 |
| Scpharmaceuticals Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Carto 3$2,234
- EMBLEM MRI S-ICD$2,038
- Farapulse$1,172
- ENSITE PRECISION$746
- (9520) IGT Devices Undivided$727
- EVERA MRI XT DR SURESCAN$474
- ACCOLADE SR$402
- LifeVest$322
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$268
- HeartMate 3 Left Ventricular Assist Device$137
- BioMonitor$116
- Ozempic$114
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 31 | $22,392 |
| Repatha SureclickEvolocumab | 13 | $7,105 |
| Metoprolol Succinate | 20 | $314 |
| Amiodarone Hcl | 20 | $178 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $43 | $22,39231 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Mississippion file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.